-

Alexion to Present at the 39th Annual J.P. Morgan Healthcare Conference

BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that management will present virtually at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12th at 7:30 a.m. ET.

Audio webcasts of the presentations will be available live at: http://ir.alexion.com. Archived versions of the remarks will also be available through the Company’s website for a limited time following the conferences.

[ALXN-G]

Contacts

Investors
Chris Stevo
Head of Investor Relations
(857) 338-9309

Industry:

Alexion Pharmaceuticals

NASDAQ:ALXN
Release Summary
Alexion to Present at the 39th Annual J.P. Morgan Healthcare Conference
Release Versions
English

Contacts

Investors
Chris Stevo
Head of Investor Relations
(857) 338-9309

More News From Alexion Pharmaceuticals

Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized Myasthenia Gravis (gMG)

BOSTON--(BUSINESS WIRE)--Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized Myasthenia Gravis (gMG)....

Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amyloidosis at the European Hematology Association Congress 2021

BORDENTOWN, N.J. & BOSTON--(BUSINESS WIRE)--Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amyloidosis at the EHA Congress 2021...

 Alexion Announces FDA Approval of ULTOMIRIS® (ravulizumab-cwvz) for Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH)

BOSTON--(BUSINESS WIRE)--Alexion Announces FDA Approval of ULTOMIRIS® (ravulizumab-cwvz) for Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH)...
Back to Newsroom